Abstract

Compounding with Beta-1, 3-D-Glucan

Author(s): Keller Ted

Issue: Sep/Oct 2000 - Compounding for Immune System Disorders

Page(s): 342

Download in electronic PDF format for $75
  • Compounding with Beta-1, 3-D-Glucan Page 1

Abstract

Beta-1,3-D-glucan, a homopolymer of glucose, is a brown powder consisting of beta-1,3-linked glucopyranose polymers, which are insoluble molecules in all solvents. In this article, various therapeutic applications of beta-1,3-D-glucan and its effect on the role of the macrophage in immune system functioning are presented. The author focuses on infectious diseases; allergy and breathing disorders; neoplastic disease and the side effects of treatment; diabetes, hypertension, cholesterol and liver disease; autoimmune disorders; dermatologic applications and additional benefits of treatment. She also provides four very brief case reports. She concludes that beta-1,3-D-glucan is a powerful adjunct to the treatment of several disorders and should be included in every compounding practice. Its disadvantage is that, if treatment fails, the expense of therapy has been wasted; however, therapeutic failures are infrequent.

Related Keywords

  • glucan
  • beta-1,3-D
  • infectious disease

Related Categories

  • NUTRITION AND NUTRICEUTICALS

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Sep/Oct 2000
Pg. 342
Compounding with Beta-1, 3-D-Glucan
Author(s): Keller Ted
Jul/Aug 2003
Pg. 288-291
Basics of Compounding for Raynaud's Disease
Author(s): Glasnapp Andrew
May/Jun 2020
Pg. 194-197
Compounded Beta-blocker Nasal Spray for Treatment of Acute Migraine: A New Therapeutic Modality
Author(s): Hagan John C III, Everett Eric, Chamberlain Tyler
Sep/Oct 2022
Pg. 364-368
A Compendium of Compounding Agents and Formulations, Part 5: Timolol and Beta-glucans
Author(s): Riepl Mike
May/Jun 2003
Pg. 188-191
Treating Canine Hepatic Disease
Author(s): Davidson Gigi S
May/Jun 2004
Pg. 181-185
Compounding in the Pharmacy Curriculum: Beyond the Basics
Author(s): Hinkle Amanda R, Newton Gail D
Nov/Dec 2007
Pg. 520-524
Palonosetron Hydrochloride Compatibility and Stability with Three Beta-Lactam Antibiotics During Simulated Y-Site Administration
Author(s): Ben Michel, Trusley Craig, Kupiec Thomas C, Trissel Lawrence A
Nov/Dec 2011
Pg. 458-463
Infantile Hemangiomas, Part 2: Topical Treatment with Beta Blockers
Author(s): Zur Eyal
Jul/Aug 2016
Pg. 328-332
Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures
Author(s): Foushee Jaime A, Meredith Pmichaele, Fox Laura M, Grace EdwardE
Nov/Dec 2011
Pg. 450-457
Compounding for Treatment of Equine Infectious Diseases: An Overview
Author(s): Bramwell Bethany L
Jul/Aug 2004
Pg. 269-274
Current Topical Treatments in Wound Healing - Part 1
Author(s): Helmke Christopher D
Mar/Apr 2024
Pg. 129
Addendum to Compounded Beta-blocker Nasal Spray for Treatment of Acute Migraine A New Therapeutic Modality
Author(s):
Sep/Oct 2012
Pg. 420
Esmolol Hydrochloride 10-mg/mL Injection
Author(s): Allen Loyd V Jr
Sep/Oct 2007
Pg. 384-388
Equine Cushing's Disease: A Clinical Update
Author(s): Bliss George
Jul/Aug 2022
Pg. 293-296
Compounding for Juvenile Idiopathic Arthritis and Other Pediatric Rheumatic Diseases
Author(s): Harrington Amy, Williams LaVonn
Nov/Dec 2021
Pg. 503
Metoprolol Tartrate 10 mg/mL in SyrSpend SF pH4 Oral Suspension
Author(s): Allen Loyd V Jr
May/Jun 2004
Pg. 206-209
Basics of Compounding for Cold Sores or Fever Blisters
Author(s): Allen Loyd V Jr
May/Jun 2003
Pg. 170-174
Five Compounds for Treating Diabetes-Related Conditions
Author(s): Meece Jerry
Jan/Feb 2014
Pg. 6-12
The Role of Compounding in Closing Therapeutic Gaps--Abstracts from FIP 2013
Author(s): Lutz Eugene, Pauletti Giovanni, Carvalho Maria, Davidson Gigi, Ashworth Lisa, Subramaniam Vaiyapuri, Llambí Francesc
Nov/Dec 2022
Pg. 446-466
Compounding with Biotechnology Products, Part 2: Product-specific Considerations
Author(s): Allen Loyd V Jr